聯生藥（揚州)的生物制藥研發與生產基地,占地 1.3 萬平米,提供一站式 CDMO 服務,從原液到藥品的無菌灌裝 cGMP 生產。生產規模涵蓋 50L/200L/500L/2000L,  支持前臨床和臨床的 IND 報批,以及后期 BLA 審批和早期的商業化生產。我們 團隊擁有超過 10 年的單抗和重組蛋白生產經驗, 實現了 6+個創新藥物在中國和 美國的臨床報批。持續地精進與強化生物工藝,在質量源于設計和質量風險管理 的原則下,確保產品整個生命周期的質量并且符合經濟效益。透過建立靈活的伙 伴關系,以及一體化的服務平臺: 高效敬業的項目團隊, 國際標準的質量管理, 優 質的 CMC 文件, 全方位支持客戶完成個階段的研發和報批任務。

The R&D and production base of United Biopharma(Yangzhou) covers an area of  13,000 square meters and provides one-stop CDMO services for cGMP production of  drug substance and drug product by aseptic filling, which production scale includes  50L/200L/500L/2000L, supporting pre-clinical and clinical IND approval, as well as  the later BLA approval and early commercial production. Our team has more than 10  years of experience in the production of mAb and recombinant proteins, and has  achieved clinical approval of 6+ innovative biologics in China and the United States.  Continue to improve and intensify the bioprocess, meanwhile ensure the product quality  during R&D life cycle, balanced with the economic benefits under implementing quality-by-design and quality risk management. Through the establishment of flexible  partnerships, and an integrated service platform: efficient and dedicated project team,  international standard quality management, high-quality CMC documents, all-round  support for our clients to accomplish each R&D stage and IND approval tasks.